

# A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray

NCT07259538

---

Status	RECRUITING
Phase	Phase 1
Sponsor	VivaVision Biotech, Inc
Enrollment	60 participants

## Key Eligibility Criteria

---

### Inclusion (11)

- Part 1:
- Healthy male or female subjects aged 18 to 55 years old (inclusive);
- Body weight  $\geq 50.0$  kg for males and  $\geq 45.0$  kg for females; body mass index (BMI) within the range of 18.5 to 28.0 kg/m<sup>2</sup> (inclusive);
- No clinically significant abnormalities at screening or baseline.

• Part 2:

... and 6 more (see full listing online)

### Exclusion (11)

- Part 1:
- Known hypersensitivity or contraindications to the study drug or its components;
- History or current conditions that affect the safety or absorption of the investigational drug;
- History of drug abuse or drug dependence;
- Participation in any other clinical trials and receiving an investigational drug within 12 weeks before screening or 5 half-lives, whichever is longer;

... and 6 more (see full listing online)

## Locations (1 total)

---

Beijing Toren Hospital, Beijing, China